Current Report Filing (8-k)
July 13 2017 - 3:30PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant To Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
June 13, 2017
PSYCHEMEDICS CORPORATION
(
Exact Name
of Registrant As Specified In Its Charter
)
Delaware
(
State or
Other Jurisdiction of Incorporation
)
1-13738
|
58-1701987
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
125 Nagog Park, Acton, Massachusetts
|
01720
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(978) 206-8220
(Registrant’s Telephone Number, Including
Area Code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
|
ITEM 5.02
|
DEPARTURE OF DIRECTORS OF CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS
OF CERTAIN OFFICERS
|
On June 13, 2017, Mr. James V.
Dyke, the Company’s Corporate Vice President of Sales and Marketing, notified the Company of his decision to resign his position
to pursue other interests. His last day of employment was July 11, 2017.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PSYCHEMEDICS CORPORATION
|
Dated: July 13, 2017
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Neil L. Lerner
|
|
|
Neil L. Lerner,
|
|
|
Vice President - Finance
|
Psychemedics (NASDAQ:PMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Psychemedics (NASDAQ:PMD)
Historical Stock Chart
From Sep 2023 to Sep 2024